Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 114 clinical trials
Pembrolizumab in Combination With Gemcitabine in People With Advanced Mycosis Fungoides or Sézary Syndrome

The purpose of this study is to find out whether the combination of pembrolizumab and gemcitabine is an effective treatment for mycosis fungoides and Sézary syndrome.

adrenal insufficiency
pet scans
mycosis
erythropoietin
metastases
  • 0 views
  • 07 Jul, 2022
  • 7 locations
Phase 1B, Pilot Study to Assess the Pharmacodynamics, Pharmacokinetics, Safety, Activity of Pembrolizumab Administered Intra-lymphatically Using the Sofusa® DoseConnect™ in Patients With Relapsed/Refractory Cutaneous T- Cell Lymphoma (CTCL)

In this pilot study, pembrolizumab will be administered via DoseConnect in patient with relapsed or refractory cutaneous T-cell lymphoma to assess through pharmacodynamic assessment in the tumor tissue to assess if lymphatic delivery of pembrolizumab using Sofusa DoseConnect is feasible.

mycosis
brentuximab
cutaneous t-cell lymphoma
t-cell lymphoma
lymphoma
  • 0 views
  • 22 Oct, 2022
  • 1 location
Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis Fungoides

To learn if a form of radiation therapy (called ultra-low-dose - total skin electron beam therapy [ULD-TSEBT]) in combination with brentuximab vedotin can help to control mycosis fungoides

  • 0 views
  • 23 Oct, 2022
  • 1 location
Naloxone Hydrochloride Study for Relief of Pruritus in Patients With MF or SS Forms of CTCL

pruritus in patients with the mycosis fungoides (MF) or Sézary syndrome (SS) Forms of Cutaneous T-cell Lymphoma (CTCL). This study will also determine if there is systemic absorption of the drug in a

mycosis
t-cell lymphoma
cutaneous t-cell lymphoma
naloxone hydrochloride
skin biopsy
  • 0 views
  • 26 Mar, 2022
  • 19 locations
A Phase 1b/2 Study of Hu5F9-G4 (Magrolimab) in Combination With Mogamulizumab in Relapsed/Refractory Treated T-Cell Lymphoma

This phase Ib/II trial identifies the best dose and possible benefits and/or side effects of magrolimab when given in combination with mogamulizumab in treating patients with stage IB-IV mycosis

pet scans
mycosis
anticancer agents
metastases
gilbert's syndrome
  • 2 views
  • 22 Oct, 2022
  • 2 locations
A Study of LNK01002 in Patients With Primary (PMF) or Secondary Myelofibrosis (PV-MF ET-MF) or Acute Myeloid Leukemia

This multicenter, open-label, phase 1 study designed to evaluate safety and tolerability of multi-kinase inhibitor LNK01002 in patients with primary myelofibrosis (MF), or MF due to polycythemia

refractory acute myeloid leukemia (aml)
  • 0 views
  • 17 Jun, 2021
  • 3 locations
A Phase I Study With an Expansion Cohort of Duvelisib and Nivolumab in Mycosis Fungoides (MF) and Sezary Syndrome (SS)

This phase I trial identifies the best dose, possible benefits, and/or side effects of duvelisib in combination with nivolumab in treating patients with stage IIB-IVB mycosis fungoides and

  • 7 views
  • 24 Oct, 2022
  • 5 locations
Tagraxofusp (SL-401) in Patients With CMML or MF

(MF). There are two CMML cohorts, one enrolling patients with CMML (CMML-1 or CMML-2) who are refractory/resistant or intolerant to hypomethylating agents (HMA), hydroxyurea (HU), or intensive

myelomonocytic leukemia
platelet count
leukemia
thrombocytosis
cmml-2
  • 145 views
  • 10 May, 2022
  • 10 locations
REACH: Study to Determine the Aetiology of Chlormethine Gel Induced-skin Drug Reaction in Early Stage Mycosis Fungoides Cutaneous T Cell Lymphoma (MF-CTCL) (REACH)

Adult patients with early stage MF-CTCL (stage IA-IB) will be eligible for this study. A total of 100 early stage MF-CTCL patients diagnosed in the past year will be enrolled. Treatment

  • 0 views
  • 04 Oct, 2022
  • 1 location
Selinexor in Myelofibrosis Refractory or Intolerant to JAK1/2 Inhibitors (ESSENTIAL)

This is a phase II, open label, prospective, single-arm study evaluating the efficacy and safety of selinexor in patients with PMF or secondary MF (PPV-MF or PET-MF) who are refractory or

ruxolitinib
erythropoietin
hemolysis
granulocyte colony stimulating factor
thrombocytosis
  • 13 views
  • 25 May, 2022
  • 1 location